These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 14964917)

  • 21. Drug for moderate to advanced Alzheimer's approved.
    Mayo Clin Health Lett; 2004 Feb; 22(2):4. PubMed ID: 15032170
    [No Abstract]   [Full Text] [Related]  

  • 22. Symptomatic therapeutic aspects in Alzheimer's disease.
    Gauthier S
    Handb Clin Neurol; 2008; 89():269-71. PubMed ID: 18631751
    [No Abstract]   [Full Text] [Related]  

  • 23. [The clinical relevance of memantine use].
    Sobów T
    Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapies for Alzheimer's disease.
    Melnikova I
    Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055
    [No Abstract]   [Full Text] [Related]  

  • 26. Memantine (Namenda) for moderate to severe Alzheimer's disease.
    Ables AZ
    Am Fam Physician; 2004 Mar; 69(6):1491-2. PubMed ID: 15053415
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not?
    Xiong G; Doraiswamy PM
    Geriatrics; 2005 Jun; 60(6):22-6. PubMed ID: 15948662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memantine in moderate-to-severe Alzheimer's disease.
    Bleich S; Wiltfang J; Kornhuber J
    N Engl J Med; 2003 Aug; 349(6):609-10; author reply 609-10. PubMed ID: 12904528
    [No Abstract]   [Full Text] [Related]  

  • 31. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
    Van Dam D; De Deyn PP
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):59-69. PubMed ID: 16095884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Schneider LS
    N Engl J Med; 2012 Mar; 366(10):957-9. PubMed ID: 22397659
    [No Abstract]   [Full Text] [Related]  

  • 33. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Suzuki T
    N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670911
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dementia].
    Diehl RR
    Fortschr Neurol Psychiatr; 2003 Nov; 71(11):617-28. PubMed ID: 14608514
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New therapeutic options in Alzheimer's disease].
    García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
    Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine: pharmacological properties and clinical uses.
    Kumar S
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors affecting usage patterns of memantine in Alzheimer disease.
    Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA
    Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Finucane MM; Finucane TE
    N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670912
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.